Stelazine

Schizophrenia, Alzheimer's Disease, Agitation + 2 more

Treatment

4 FDA approvals

20 Active Studies for Stelazine

What is Stelazine

Trifluoperazine

The Generic name of this drug

Treatment Summary

Prochlorperazine is a medication used to treat psychotic symptoms (such as hallucinations and delusions) and to reduce nausea and vomiting. It is a type of phenothiazine, similar to the drug chlorpromazine, and works by blocking certain types of receptors in the brain.

Trifluoperazine Hydrochloride

is the brand name

image of different drug pills on a surface

Stelazine Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Trifluoperazine Hydrochloride

Trifluoperazine

1981

36

Approved as Treatment by the FDA

Trifluoperazine, otherwise called Trifluoperazine Hydrochloride, is approved by the FDA for 4 uses such as Schizophrenia and Schizophrenia .

Schizophrenia

Helps manage Schizophrenia

Schizophrenia

Helps manage Schizophrenia

Anxiety

Helps manage acute non-psychotic Anxiety

Schizophrenia

Helps manage Schizophrenia

Effectiveness

How Stelazine Affects Patients

Trifluoperazine is a type of drug used to treat schizophrenia and other mental health conditions. It has not been found to be helpful in treating behavioral issues in people with intellectual disabilities.

How Stelazine works in the body

Trifluoperazine affects the chemical balance in the brain by blocking certain dopamine receptors. It also decreases the release of hormones from the hypothalamus and pituitary glands, which can affect your metabolism, body temperature, alertness, blood pressure, and vomiting.

When to interrupt dosage

The quantity of Stelazine is subject to the diagnosed affliction, such as Agitation, Anxiety and Alzheimer's Disease. The dosage changes, contingent upon the delivery technique (e.g. Tablet, film coated - Oral or Oral) detailed in the table beneath.

Condition

Dosage

Administration

Alzheimer's Disease

1.0 mg, , 2.0 mg, 5.0 mg, 10.0 mg, 20.0 mg, 1.18 mg, 2.36 mg, 5.9 mg, 11.8 mg, 23.6 mg, 10.0 mg/mL, 1.0 mg/mL

Oral, Tablet, film coated, , Tablet, film coated - Oral, Tablet - Oral, Tablet, Syrup - Oral, Syrup

Schizophrenia

1.0 mg, , 2.0 mg, 5.0 mg, 10.0 mg, 20.0 mg, 1.18 mg, 2.36 mg, 5.9 mg, 11.8 mg, 23.6 mg, 10.0 mg/mL, 1.0 mg/mL

Oral, Tablet, film coated, , Tablet, film coated - Oral, Tablet - Oral, Tablet, Syrup - Oral, Syrup

Agitation

1.0 mg, , 2.0 mg, 5.0 mg, 10.0 mg, 20.0 mg, 1.18 mg, 2.36 mg, 5.9 mg, 11.8 mg, 23.6 mg, 10.0 mg/mL, 1.0 mg/mL

Oral, Tablet, film coated, , Tablet, film coated - Oral, Tablet - Oral, Tablet, Syrup - Oral, Syrup

Schizophrenia

1.0 mg, , 2.0 mg, 5.0 mg, 10.0 mg, 20.0 mg, 1.18 mg, 2.36 mg, 5.9 mg, 11.8 mg, 23.6 mg, 10.0 mg/mL, 1.0 mg/mL

Oral, Tablet, film coated, , Tablet, film coated - Oral, Tablet - Oral, Tablet, Syrup - Oral, Syrup

Anxiety

1.0 mg, , 2.0 mg, 5.0 mg, 10.0 mg, 20.0 mg, 1.18 mg, 2.36 mg, 5.9 mg, 11.8 mg, 23.6 mg, 10.0 mg/mL, 1.0 mg/mL

Oral, Tablet, film coated, , Tablet, film coated - Oral, Tablet - Oral, Tablet, Syrup - Oral, Syrup

Warnings

Stelazine has five contraindications and should not be administered when suffering from any of the conditions laid out in the table below.

Stelazine Contraindications

Condition

Risk Level

Notes

Coma

Do Not Combine

preexisting liver damage

Do Not Combine

Bone Marrow

Do Not Combine

greatly depression

Do Not Combine

existing blood dyscrasias

Do Not Combine

There are 20 known major drug interactions with Stelazine.

Common Stelazine Drug Interactions

Drug Name

Risk Level

Description

Acepromazine

Major

Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Alfuzosin

Major

Trifluoperazine may increase the hypotensive activities of Alfuzosin.

Amisulpride

Major

Trifluoperazine may increase the antipsychotic activities of Amisulpride.

Aripiprazole

Major

Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.

Aripiprazole lauroxil

Major

Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole lauroxil.

Stelazine Toxicity & Overdose Risk

The symptoms of an overdose on Atenolol may include agitation, loss of consciousness, seizures, difficulty breathing or swallowing, dry mouth, excessive drowsiness, fever, blocked intestines, abnormal heart rate, low blood pressure, and restlessness.

Stelazine Novel Uses: Which Conditions Have a Clinical Trial Featuring Stelazine?

453 active studies are being conducted to appraise the effectiveness of Stelazine in treating Anxiety, Agitation and Schizophrenic symptoms.

Condition

Clinical Trials

Trial Phases

Alzheimer's Disease

118 Actively Recruiting

Phase 4, Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1

Schizophrenia

89 Actively Recruiting

Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2, Phase 3

Schizophrenia

34 Actively Recruiting

Early Phase 1, Not Applicable, Phase 4, Phase 3

Agitation

8 Actively Recruiting

Phase 3, Phase 2, Not Applicable

Anxiety

0 Actively Recruiting

Stelazine Reviews: What are patients saying about Stelazine?

5

Patient Review

6/19/2010

Stelazine for Mental Disorder with Loss of Normal Personality & Reality

This medication has been a life-saver for me. It's allowed me to think clearly and be myself again.

5

Patient Review

9/27/2018

Stelazine for Mental Disorder with Loss of Normal Personality & Reality

This treatment was great! It helped me a lot.

5

Patient Review

3/15/2010

Stelazine for Schizophrenia

Olanzapine 10mgs a day Mirtazapine Zopiclone 15 mgs nocte

4

Patient Review

1/20/2011

Stelazine for Mental Disorder with Loss of Normal Personality & Reality

Stelazine 4mg was really effective when other treatments didn't work for my bipolar disorder. I don't love the side effects (tremors and loss of libido) but they're manageable.

4

Patient Review

9/13/2012

Stelazine for Anxious

This drug was effective for me.

3

Patient Review

7/14/2014

Stelazine for Anxious

I felt pretty sedated and tired after taking this, and experienced some dizziness.

1

Patient Review

7/15/2009

Stelazine for Mental Disorder with Loss of Normal Personality & Reality

This treatment is ineffective and dangerous. It's like treating asthma with Zyklon B.

1

Patient Review

8/21/2008

Stelazine for Mental Disorder with Loss of Normal Personality & Reality

1

Patient Review

1/9/2010

Stelazine for Anxious

I was on a 5 mg dose of this drug for 8 years, and then my neurologist put me on Risperdal 2 mg for 18 years. He said that this contributed to my development of Parkinson's disease.

Patient Q&A Section about stelazine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the drug Stelazine used for?

"It can also reduce unwanted/uncontrolled movements (such as twitching, fidgeting, muscle stiffness).

Trifluoperazine is used for treating mental/mood disorders such as schizophrenia and psychotic disorders. It can help patients think more clearly, feel less nervous, and take part in everyday life. Trifluoperazine can also reduce aggressive behavior, the desire to hurt oneself/others, and unwanted/uncontrolled movements (such as twitching, fidgeting, and muscle stiffness)."

Answered by AI

How long can you take Stelazine?

"Stelazine (trifluoperazine) should not be used to treat non-psychotic anxiety at doses higher than 6 mg per day or for longer than 12 weeks. Higher doses or longer intervals of use may cause persistent tardive dyskinesia."

Answered by AI

Why is Stelazine discontinued?

"Trifluoperazine can cause extrapyramidal side effects, which are abnormal muscle contractions, difficulty breathing and swallowing, and neck spasms."

Answered by AI

Is Stelazine still available?

"Stelazine is no longer available as a brand-name medication. It can only be found in generic form."

Answered by AI

Clinical Trials for Stelazine

Image of Brigham and Women's Hospital in Boston, United States.

Acute Exercise for Parkinson's Disease

18+
All Sexes
Boston, MA

The goal of this study is to investigate how a one-time exercise session influences different parameters of brain function in people with neurological diseases compared to healthy volunteers. The main questions the study aims to answer are: * How do fitness level, exercise performance, and physical exhaustion differ between patients with neurological diseases and healthy participants? * How does acute exercise affect brain function and other physiological biomarkers in participants with neurological diseases? Participants will take part in a single, one-day study visit and will be asked to: * Perform a standardized exercise test on a bicycle ergometer * Undergo a brain MRI (magnetic resonance imaging) scan, a blood draw, and autonomic measurements before and after the exercise test

Recruiting
Has No Placebo

Brigham and Women's Hospital

Claus Reinsberger, MD, PhD

Image of University of California, Davis in Davis, United States.

HomeCare for Dementia

65+
All Sexes
Davis, CA

This study will evaluate whether the HomeCare medication management system can improve medication adherence and related outcomes for adults age 65 and older living with dementia, Alzheimer's disease, or related dementias. HomeCare is an internet-connected medication management device that can automate medication dispensing, monitor medication use, and provide alerts to caregivers. The system is integrated with a Pharmacy Distribution System designed to track medications from pharmacy delivery through use in the home. A total of 120 participants with dementia will be randomly assigned to one of two groups. One group will use the HomeCare system, while the other group will continue using standard medication management methods, such as pill bottles or blister packs. Participants will be followed for 12 months. The main outcome is medication adherence. The study will also examine hospitalizations and emergency room visits, cognitive function, caregiver burden, quality of life, satisfaction, and changes in medication-management behavior. Caregivers will also participate in surveys and study assessments. The study is intended to determine whether HomeCare can improve medication management and support both people living with dementia and their caregivers.

Waitlist Available
Has No Placebo

University of California, Davis

HiDO Technologies

Image of Northwestern University Feinberg School of Medicine in Chicago, United States.

Negotiation Training for Caregivers of Alzheimer's Disease

18+
All Sexes
Chicago, IL

Family caregivers of people living with Alzheimer's disease and related dementias often experience conflicts and communication challenges when coordinating care, making decisions, and interacting with family members and healthcare providers. These challenges can contribute to caregiver burden, stress, anxiety, and reduced well-being. The purpose of this study is to evaluate the effectiveness of NegotiAge, an online negotiation and communication training program designed for family caregivers. NegotiAge provides education and interactive practice exercises to help caregivers develop negotiation, problem-solving, conflict-resolution, and communication skills that can be applied to real-world caregiving situations. Approximately 200 family caregivers will be randomly assigned to either the NegotiAge intervention or an attention-control educational website. Participants will complete online surveys before the intervention, immediately after the intervention, and at 1-month and 3-month follow-up time-points. The study will examine whether NegotiAge reduces caregiver burden and improves communication, conflict-management behaviors, self-efficacy, stress, anxiety, fatigue, and well-being. Findings from this research may help improve support programs for family caregivers of people living with Alzheimer's disease and related dementias.

Waitlist Available
Has No Placebo

Northwestern University Feinberg School of Medicine

Have you considered Stelazine clinical trials?

We made a collection of clinical trials featuring Stelazine, we think they might fit your search criteria.
Go to Trials
Image of Duke University in Durham, United States.

Jigsawdio Multisensory Platform for Dementia

18+
All Sexes
Durham, NC

This study will evaluate Jigsawdio, a personalized multisensory jigsaw puzzle platform, for adults aged 60 years and older with mild cognitive impairment or mild dementia. Approximately 80 participants will be randomly assigned to either the Jigsawdio group or a control group using standard dementia-friendly jigsaw puzzles. Both groups will complete two 30- to 40-minute puzzle sessions per week for six weeks, for a total of 12 sessions. Jigsawdio combines transparent physical puzzle pieces with personalized images, stories, and audio presented through an iPad. The study will compare changes in depression, anxiety, quality of life, cognition, engagement, satisfaction, and program feasibility. Assessments will be completed at baseline, after the six-week program, and at a 12-week follow-up. Information may also be collected from participants' caregivers or informants.

Waitlist Available
Has No Placebo

Duke University (+1 Sites)

Maria Marquine, PhD

Callahan-Young LLC DBA Jigsawdio

Image of Dartmouth Health in Lebanon, United States.

ACP Counselor Video Program for Alzheimer's Disease

65+
All Sexes
Lebanon, NH

The goal of this clinical trial is to make sure that the values of older persons aged 65 years or older with Alzheimer's Disease and Related Dementias (ADRD) or increased risk of mortality are known and respected, thereby reducing the burden of intrusive, unwanted medical interventions on their lives. The main aims of the study are: * To assess the impact of our Advance Care Planning (ACP) Counselor Video Program on ACP documentation and receipt of goal-concordant care in a diverse sample of older adults with ADRD or other serious illness * To compare resuscitation preferences, hospice use, healthcare utilization and costs Researchers will randomize participants into two groups. All participants will continue to receive routine care. Participants randomized to the Immediate-Start Intervention group will be offered the ACP Counselor Video Program during both Phase 1 and Phase 2. Participants randomized to the Routine Care/Delayed-Start Intervention group will receive routine care alone during Phase 1 and will be offered the ACP Counselor Video Program beginning in Phase 2. Each phase will last two years. Both groups will have access to the intervention during Phase 2. During the intervention, participants will: * Meet with ACP counselors * Watch ACP videos.

Waitlist Available
Has No Placebo

Dartmouth Health (+1 Sites)

Michael Paasche-Orlow

Image of Center for Magnetic Resonance Research, University of Minnesota in Minneapolis, United States.

Cognitive Training for Schizophrenia

18 - 79
All Sexes
Minneapolis, MN

This study will examine brain metabolic and excitatory/inhibitory mechanisms related to cognitive and visual functioning in adults with schizophrenia and healthy control participants. Participants will complete behavioral assessments, cognitive testing, electroencephalography, magnetic resonance imaging, and magnetic resonance spectroscopy assessments. After baseline assessments, participants will be randomly assigned to one of two computerized cognitive training programs: perceptual discrimination training or cognitive control training. Each training program will include approximately 10 hours of training over 2 to 6 weeks. The study will evaluate changes in cognitive and visual task performance, EEG measures, and brain metabolite concentrations before and after cognitive training. Some participants may also complete optional extended baseline assessments before cognitive training.

Waitlist Available
Has No Placebo

Center for Magnetic Resonance Research, University of Minnesota

Caroline Demro, PhD, LP

Image of University Of Minnesota in Minneapolis, United States.

Treatment for Dementia

18+
All Sexes
Minneapolis, MN

This study will evaluate the Social Reminder System, a mobile informatics system designed to support persons with memory concerns and their care partners. The system is intended to aid social integration for persons with memory concerns and improve care coordination and reduce caregiver burden among caregivers. Researchers will enroll 100 persons with memory concerns and their care partners. Half of the dyads will be randomly assigned to receive the Social Reminder System technology for a 6-month period, and the other half will be randomly assigned to the usual care control group. Participants will complete baseline, 3-month, and 6-month surveys. A subset of participants who receive the technology will also be asked to complete a semi-structured interview after the 6-month survey.

Waitlist Available
Has No Placebo

University Of Minnesota

Jude Mikal, PhD

Have you considered Stelazine clinical trials?

We made a collection of clinical trials featuring Stelazine, we think they might fit your search criteria.
Go to Trials
Image of Weill Cornell Medicine in New York, United States.

Treatment for Dementia

18+
All Sexes
New York, NY

The goal of this clinical trial is to evaluate the impact of screening for elder neglect in older adults with dementia in primary care settings and the impact of an intervention for caregivers of older adults with dementia. The hypothesis of the study are: * Neglect screening in primary care will have a positive impact on outcomes including a decrease in presence of neglect at 6 months and other patient and caregiver outcomes * Neglect screening paired with a caregiving intervention will have a greater impact on these outcomes than screening alone Researchers will compare three groups of participants to find out how effective the screening tool is on its own, and how effective it is when combined with the support program, compared to standard care. Participants will be asked to: * attend primary care clinic visits * complete questionnaires * participate in the intervention * participate in a semi-structured interview

Waitlist Available
Has No Placebo

Weill Cornell Medicine

Tony Rosen, MD

Image of University of California, Los Angeles in Los Angeles, United States.

Suicide Prevention Program for Suicidal Thoughts

12 - 30
All Sexes
Los Angeles, CA

Young people at clinical high risk for psychosis are more likely to experience suicide thoughts than the general population, but there are few suicide prevention programs designed specifically for them. This study will develop and evaluate a recovery-oriented suicide prevention group program for young people at clinical high risk for psychosis. The program will be led by a clinician and a peer with lived experience. It will help participants identify reasons for living, build hope, set meaningful recovery goals, strengthen social connections, and learn strategies to better remember and use suicide prevention strategies developed during the program. Caregivers will also be invited to participate in a session to learn ways to support their young person. The study will first gather feedback from participants, caregivers, clinicians, and community advisors to refine the program. Researchers will then compare the program plus standard care with standard care alone to determine whether it improves personal recovery and increases participants' ability to remember and use suicide prevention strategies. Researchers will also collect feedback from participants and program staff to better understand how the program can be integrated into early psychosis services.

Recruiting
Has No Placebo

University of California, Los Angeles (+1 Sites)

Image of London Health Sciences Centre (LHSC) in London, Canada.

BASIC-S Intervention for Cardiovascular Risk

18+
All Sexes
London, Canada

Vascular risk factors drive stroke, heart disease, and dementia, but translating lifestyle guidelines into routine clinical care remains challenging. To address this, we developed BASIC-S (Blood Pressure, Activity, Sleep, Interaction, Consumption, and Support), a framework targeting Blood pressure, Activity, Sleep, Interaction (socially), Consumption (nutrition), and Support using partner support and motivational interviewing. This individual-focused approach bypasses the logistical and financial barriers of complex clinical interventions by using sustained behavioral science to support gradual lifestyle changes. This study is a single-center, mixed-methods, cluster-randomized pilot trial evaluating the feasibility of the BASIC-S protocol in an occupational setting. A maximum of 60 households (120 participants) will be randomized 1:1 to either the BASIC-S intervention (motivational coaching, secure video check-ins, automated text messages, and a digital workbook) or standard care. Outcomes will assess feasibility, acceptability, and the validity of new tracking metrics to inform a future full-scale trial.

Waitlist Available
Has No Placebo

London Health Sciences Centre (LHSC)

Have you considered Stelazine clinical trials?

We made a collection of clinical trials featuring Stelazine, we think they might fit your search criteria.
Go to Trials